Skip to Content

Pfizer Inc PFE

Morningstar Rating
$27.78 +0.19 (0.69%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Pfizer: Oncology Research and Development Presentation Highlights Next-Generation Blockbusters

We are holding firm to our fair value for Pfizer following the firm’s oncology research and development presentation that showed a strong lineup of new potential blockbusters. The wide breadth of Pfizer’s cancer drug pipeline reinforces our undervalued view of the stock, as the market appears to underappreciate the company’s pipeline. The strong pipeline also reinforces Pfizer’s wide moat rating.

Price vs Fair Value

PFE is trading at a 35% discount.
Price
$27.43
Fair Value
$46.00
Uncertainty
Medium
1-Star Price
$66.80
5-Star Price
$88.20
Economic Moat
Ccty
Capital Allocation
Trmklbqc

Bulls Say, Bears Say

Bulls

Pfizer's pipeline productivity is improving with several successful recent drug launches. In particular, cardiovascular drug Vyndaqel is a potential game-changer in the rare-disease arena.

Bears

Aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment in innovation.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PFE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$27.59
Day Range
$27.5427.94
52-Week Range
$25.6142.22
Bid/Ask
$27.80 / $27.81
Market Cap
$157.31 Bil
Volume/Avg
1,728 / 41.2 Mil

Key Statistics

Price/Earnings (Normalized)
15.10
Price/Sales
2.68
Dividend Yield (Trailing)
5.94%
Dividend Yield (Forward)
6.05%
Total Yield
5.94%

Company Profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
88,000

Competitors

Valuation

Metric
PFE
LLY
MRK
Price/Earnings (Normalized)
15.1092.7587.83
Price/Book Value
1.7668.588.88
Price/Sales
2.6820.605.58
Price/Cash Flow
14.4296.3522.06
Price/Earnings
PFE
LLY
MRK

Financial Strength

Metric
PFE
LLY
MRK
Quick Ratio
0.580.520.68
Current Ratio
0.910.941.25
Interest Coverage
0.7414.132.33
Quick Ratio
PFE
LLY
MRK

Profitability

Metric
PFE
LLY
MRK
Return on Assets (Normalized)
4.98%10.22%3.59%
Return on Equity (Normalized)
10.90%52.03%9.12%
Return on Invested Capital (Normalized)
7.28%19.27%5.88%
Return on Assets
PFE
LLY
MRK
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoQfqmywvgrxMkh$739.9 Bil
JNJ
Johnson & JohnsonTdptmlgqXjs$380.6 Bil
MRK
Merck & Co IncPxhqxsqdtNlvjf$333.7 Bil
ABBV
AbbVie IncChqwkwczZqqz$319.3 Bil
AZN
AstraZeneca PLC ADRBljslktphZfpj$210.3 Bil
RHHBY
Roche Holding AG ADRKhsyrtbdqHbz$201.6 Bil
NVS
Novartis AG ADRGtnvmjtJbvc$196.0 Bil
AMGN
Amgen IncWbwmpdslcHzlcv$153.4 Bil
SNY
Sanofi SA ADRQsvwzqnpQscb$124.1 Bil

Sponsor Center